Peter Zhang: Is Canada Ready for the Gene Therapy Era?
Peter Zhang, Director, Business Acceleration at Odaia, shared a post on LinkedIn:
”My latest in The Hill Times on gene therapies, and whether the Canadian healthcare system is ready for these innovative medicines.
When I was a board member with Hemophilia Ontario (now known as Bleeding Disorders Ontario), I was excited to hear about its patient impact firsthand.
This year, a Canadian with severe hemophilia B received the first gene therapy approved in Canada. But a single dose can cost more than $4 million, and payers need to approach patient access in an equitable and sustainable manner.
Canada also needs to consider its strategy for future innovations in gene therapy and it’s encouraging that there is ongoing work to leverage this technology to introduce therapies for patients living with Huntington’s disease, spinal muscular atrophy, and inherited retinal diseases.”
Stay updated with Hemostasis Today.
-
Oct 12, 2026, 21:51Sam Botchey: Orthobiologics Are Advancing but the Evidence Must Keep Pace
-
Oct 12, 2026, 21:50Serum Vitamin D, Platelet Function, and Bleeding in Primary ITP – Platelets Journal
-
Oct 12, 2026, 21:30Nika Samadzadeh Tabrizi: Looking Forward to the PACeS Trial on Anticoagulation for POAF
-
Oct 12, 2026, 21:28Michael Megaly: Does Coronary Ectasia Affect Outcomes in Acute Coronary Syndromes?
-
Oct 12, 2026, 21:25Vitor Borin P. de Souza: Think Twice Before Anticoagulating an Isolated Subsegmental PE
-
Oct 12, 2026, 20:43Jazlyn A Selvasingh: Excited to Share Our Research at AAO-HNSF 2026 in Los Angeles
-
Oct 12, 2026, 20:31Natalia Kovtun: Higher Ferritin Cutoffs Now Define Iron Deficiency
-
Oct 12, 2026, 19:39Edward Loftus: Using Low-Dose Aspirin in Pregnant Women With IBD
-
Oct 12, 2026, 19:32Shruti Sachdeva: Strengthening the Fight against Anemia